Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Oct, 2016 | Pages:
186 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Review, H2 2016', provides in depth analysis on Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted pipeline therapeutics. The report provides comprehensive information on the Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics development and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note: *Certain sections in the report may be removed or altered based on the availability and relevance of data. *Updated report will be delivered in 48 hours of order confirmation. Scope - The report provides a snapshot of the global therapeutic landscape for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - The report reviews Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics and enlists all their major and minor projects - The report assesses Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) targeted therapeutics Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) Overview 9 Therapeutics Development 10 Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Stage of Development 10 Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Therapy Area 11 Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Indication 12 Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Pipeline Products Glance 15 Late Stage Products 15 Early Stage Products 16 Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Companies 17 Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Products under Development by Universities/Institutes 30 Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Therapeutics Assessment 32 Assessment by Monotherapy/Combination Products 32 Assessment by Mechanism of Action 33 Assessment by Route of Administration 34 Assessment by Molecule Type 36 Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Companies Involved in Therapeutics Development 38 Abeome Corporation 38 Alnylam Pharmaceuticals, Inc. 39 AlphaMab Co., Ltd 40 AstraZeneca Plc 41 Aurigene Discovery Technologies Limited 42 Avacta Group Plc 43 BeiGene, Ltd. 44 Bristol-Myers Squibb Company 45 CBT Pharmaceuticals Inc 46 CytomX Therapeutics, Inc. 47 Eli Lilly and Company 48 F. Hoffmann-La Roche Ltd. 49 Genosco 51 ImmunoCellular Therapeutics, Ltd. 52 Immunocore Limited 53 IO Biotech ApS 54 Kadmon Corporation, LLC 55 Kymab Limited 56 MedImmune, LLC 57 Merck KGaA 59 Merus NV 60 Novartis AG 61 PsiOxus Therapeutics Limited 62 Regeneron Pharmaceuticals Inc 63 Shanghai Henlius Biotech Co., Ltd. 64 Sorrento Therapeutics, Inc. 65 Sutro Biopharma, Inc. 66 Theravectys SA 67 Tikcro Technologies, Ltd. 68 Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Drug Profiles 69 ALN-PDL - Drug Profile 69 Antibody to Inhibit PD-L1 for Oncology - Drug Profile 70 Antisense Oligonucleotide to Inhibit PD-L1 for Oncology - Drug Profile 71 atezolizumab - Drug Profile 72 avelumab - Drug Profile 86 AZD-1775 + durvalumab - Drug Profile 92 Biologic to Inhibit PD-L1 for Immunology - Drug Profile 93 BMS-936559 - Drug Profile 94 CA-170 - Drug Profile 96 CA-327 - Drug Profile 98 CBA-0710 - Drug Profile 99 CBT-502 - Drug Profile 100 Cellular Immunotherapy to Inhibit PD-L1 for Oncology - Drug Profile 101 CX-072 - Drug Profile 102 dabrafenib mesylate + durvalumab + trametinib dimethyl sulfoxide - Drug Profile 103 durvalumab - Drug Profile 104 durvalumab + gefitinib - Drug Profile 115 durvalumab + IMCgp-100 + tremelimumab - Drug Profile 116 durvalumab + MEDI-0562 - Drug Profile 117 durvalumab + MEDI-0680 - Drug Profile 118 durvalumab + monalizumab - Drug Profile 119 durvalumab + oleclumab - Drug Profile 120 durvalumab + selumetinib sulfate - Drug Profile 121 durvalumab + tremelimumab - Drug Profile 122 FAZ-053 - Drug Profile 126 GNS-1480 - Drug Profile 127 HLX-10 - Drug Profile 128 HLX-20 - Drug Profile 129 HTI-1316 - Drug Profile 130 IO-103 - Drug Profile 131 KD-033 - Drug Profile 132 KN-035 - Drug Profile 133 KY-1003 - Drug Profile 134 LY-3300054 - Drug Profile 135 MCLA-145 - Drug Profile 136 Monoclonal Antibodies to Inhibit PD-1/PD-L1 for Hematological Malignancies and Bacterial Infections - Drug Profile 137 Monoclonal Antibodies to Inhibit PD-L1 for Oncology - Drug Profile 138 Monoclonal Antibodies to Inhibit PD-L1 for Oncology - Drug Profile 139 Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile 140 Monoclonal Antibodies to Inhibit PDL1 for Oncology - Drug Profile 141 Monoclonal Antibody to Inhibit PD-L1 for Hematological Malignancies and Solid Tumors - Drug Profile 142 Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 143 Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 144 Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 145 Monoclonal Antibody to Inhibit PD-L1 for Oncology - Drug Profile 146 Monoclonal Antibody to Inhibit PDL-1 for Influenza - Drug Profile 147 Monoclonal Antibody to Inhibit PDL1 for Oncology - Drug Profile 148 Monoclonal Antibody to Target EGFR and to Inhibit PD-L1 for Oncology - Drug Profile 149 Oncolytic Viruses to Inhibit PDL1 for Solid Tumors - Drug Profile 150 Recombinant Proteins to Inhibit PD-L1 for Solid Tumor - Drug Profile 151 Small Molecules to Inhibit PD-L1 and PD-L2 for Oncology - Drug Profile 152 SNPDL-01 - Drug Profile 153 STIA-1011 - Drug Profile 154 STIA-1012 - Drug Profile 155 STIA-1014 - Drug Profile 156 STIA-1015 - Drug Profile 157 Synthetic Peptide 1 to Inhibit PD-L1 for Oncology - Drug Profile 158 Vaccine to Target CD274 and CD279 for Bladder Cancer - Drug Profile 159 Vaccine to Target CD274 and CD279 for Colorectal Cancer - Drug Profile 160 Vaccine to Target CD274 and CD279 for Renal Cell Carcinoma - Drug Profile 161 WBP-3155 - Drug Profile 162 Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Dormant Projects 163 Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Discontinued Products 164 Programmed Cell Death 1 Ligand 1 (PD L1 or B7 Homolog 1 or CD274) - Featured News & Press Releases 165 Appendix 181 Methodology 181 Coverage 181 Secondary Research 181 Primary Research 181 Expert Panel Validation 181 Contact Us 181 Disclaimer 182
List of Tables
Number of Products under Development for, H2 2016 14 Number of Products under Development by Therapy Area, H2 2016 15 Number of Products under Development by Indication, H2 2016 16 Comparative Analysis by Late Stage Development, H2 2016 19 Comparative Analysis by Early Stage Products, H2 2016 20 Number of Products under Development by Companies, H2 2016 21 Number of Products under Development by Companies, H2 2016 (Contd..1) 22 Products under Development by Companies, H2 2016 23 Products under Development by Companies, H2 2016 (Contd..1) 24 Products under Development by Companies, H2 2016 (Contd..2) 25 Products under Development by Companies, H2 2016 (Contd..3) 26 Products under Development by Companies, H2 2016 (Contd..4) 27 Products under Development by Companies, H2 2016 (Contd..5) 28 Products under Development by Companies, H2 2016 (Contd..6) 29 Products under Development by Companies, H2 2016 (Contd..7) 30 Products under Development by Companies, H2 2016 (Contd..8) 31 Products under Development by Companies, H2 2016 (Contd..9) 32 Products under Development by Companies, H2 2016 (Contd..10) 33 Number of Products under Investigation by Universities/Institutes, H2 2016 34 Products under Investigation by Universities/Institutes, H2 2016 35 Assessment by Monotherapy/Combination Products, H2 2016 36 Number of Products by Stage and Mechanism of Action, H2 2016 37 Number of Products by Stage and Route of Administration, H2 2016 39 Number of Products by Stage and Molecule Type, H2 2016 41 Pipeline by Abeome Corporation, H2 2016 42 Pipeline by Alnylam Pharmaceuticals, Inc., H2 2016 43 Pipeline by AlphaMab Co., Ltd, H2 2016 44 Pipeline by AstraZeneca Plc, H2 2016 45 Pipeline by Aurigene Discovery Technologies Limited, H2 2016 46 Pipeline by Avacta Group Plc, H2 2016 47 Pipeline by BeiGene, Ltd., H2 2016 48 Pipeline by Bristol-Myers Squibb Company, H2 2016 49 Pipeline by CBT Pharmaceuticals Inc, H2 2016 50 Pipeline by CytomX Therapeutics, Inc., H2 2016 51 Pipeline by Eli Lilly and Company, H2 2016 52 Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 53 Pipeline by Genosco, H2 2016 55 Pipeline by ImmunoCellular Therapeutics, Ltd., H2 2016 56 Pipeline by Immunocore Limited, H2 2016 57 Pipeline by IO Biotech ApS, H2 2016 58 Pipeline by Kadmon Corporation, LLC, H2 2016 59 Pipeline by Kymab Limited, H2 2016 60 Pipeline by MedImmune, LLC, H2 2016 61 Pipeline by Merck KGaA, H2 2016 63 Pipeline by Merus NV, H2 2016 64 Pipeline by Novartis AG, H2 2016 65 Pipeline by PsiOxus Therapeutics Limited, H2 2016 66 Pipeline by Regeneron Pharmaceuticals Inc, H2 2016 67 Pipeline by Shanghai Henlius Biotech Co., Ltd., H2 2016 68 Pipeline by Sorrento Therapeutics, Inc., H2 2016 69 Pipeline by Sutro Biopharma, Inc., H2 2016 70 Pipeline by Theravectys SA, H2 2016 71 Pipeline by Tikcro Technologies, Ltd., H2 2016 72 Dormant Projects, H2 2016 167 Discontinued Products, H2 2016 168
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
